Physician profile
Amanda Sapp
NPI 1215437405
$2,746.22
in general payments reported to CMS, 2019-2025
27 companies · $500 in 2025
The $500 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $642 · 2022: $344 · 2023: $777 · 2024: $483 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,501 · Travel and Lodging: $206 · Education: $52.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.22 |
| Travel and Lodging | $205.85 |
| Education | $52.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $875.31 | 2021-2025 | |
| Enterra Medical, INC. | $526.72 | 2023 | |
| Genzyme Corporation | $269.02 | 2025 | |
| Novo Nordisk INC | $197.79 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $154.33 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $90.84 | 2021 | |
| Mylan Specialty L.P. | $62.80 | 2022-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $59.79 | 2021 | |
| Sanofi-Aventis U.S. LLC | $52.99 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $46.41 | 2021-2025 | Airsupra |
| Grifols USA, LLC | $41.40 | 2021 | |
| Dexcom, INC. | $38.68 | 2021 | |
| Qiagen, LLC | $38.23 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $32.02 | 2024 | Voquezna |
| Qol Medical, LLC | $28.46 | 2023 | Sucraid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $27.23 | 2021 | |
| Eisai INC. | $26.23 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.10 | 2022 | |
| Braintree Laboratories, INC. | $23.03 | 2022 | |
| Intercept Pharmaceuticals, INC. | $19.19 | 2023 | Ocaliva |
| Amarin Pharma, INC. | $18.92 | 2021 | |
| Daiichi Sankyo INC. | $18.84 | 2022 | |
| Nestle Healthcare Nutrition INC. | $18.49 | 2022 | |
| Merck Sharp & Dohme LLC | $15.34 | 2021 | |
| Pfizer INC. | $14.31 | 2021 | |
| Glaxosmithkline, LLC. | $14.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Sapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.